We show that the neural network risk scores are significantly associated with levels of the blood-based ATN biomarkers of classical AD pathology—Aβ, tau phosphorylated at threonine-181 (tau/p-tau181), and NfL—which reflect the progression and severity of AD67 (Fig. 4a; Supplementary Table 22). The gene discussed is MAPT; the disease is Alzheimer disease.